GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Forward PE Ratio

Betta Pharmaceuticals Co (SZSE:300558) Forward PE Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Forward PE Ratio?

Betta Pharmaceuticals Co's Forward PE Ratio for today is 0.00.

Betta Pharmaceuticals Co's PE Ratio without NRI for today is 40.86.

Betta Pharmaceuticals Co's PE Ratio for today is 40.95.


Betta Pharmaceuticals Co Forward PE Ratio Historical Data

The historical data trend for Betta Pharmaceuticals Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Forward PE Ratio Chart

Betta Pharmaceuticals Co Annual Data
Trend
Forward PE Ratio

Betta Pharmaceuticals Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Betta Pharmaceuticals Co's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Forward PE Ratio falls into.



Betta Pharmaceuticals Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Betta Pharmaceuticals Co  (SZSE:300558) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Betta Pharmaceuticals Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines